Paper
Strained ruthenium complexes are potent light-activated anticancer agents.
Published May 11, 2012 · B. Howerton, D. Heidary, E. Glazer
Journal of the American Chemical Society
409
Citations
3
Influential Citations
Abstract
Strained ruthenium (Ru) complexes have been synthesized and characterized as novel agents for photodynamic therapy (PDT). The complexes are inert until triggered by visible light, which induces ligand loss and covalent modification of DNA. An increase in cytotoxicity of 2 orders of magnitude is observed with light activation in cancer cells, and the compounds display potencies superior to cisplatin against 3D tumor spheroids. The use of intramolecular strain may be applied as a general paradigm to develop light-activated ruthenium complexes for PDT applications.
Strained ruthenium complexes show potent light-activated anticancer properties, with 2 orders of magnitude increased cytotoxicity in cancer cells and superior potencies to cisplatin against 3D tumor spheroids.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...